News Coverage

Click to expand/collapse Jul 01, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse Jun 30, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress

Click to expand/collapse Jun 29, 2021
Click to open news item in new windowFDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

Click to expand/collapse May 26, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

Click to expand/collapse Mar 30, 2021
Click to open news item in new windowRafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse Jan 19, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Click to expand/collapse Jan 13, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Click to expand/collapse Dec 15, 2020
Click to open news item in new windowUPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

Click to expand/collapse Dec 15, 2020
Click to open news item in new windowRafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

Click to expand/collapse Dec 01, 2020
Click to open news item in new windowRafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue

   1    2   3   4